You are here: Home: BCU 7 | 2005: Rowan T Chlebowski, MD, PhD: Select publications
 
     
     
 

Select publications

Anderson GL et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women’s Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12. Abstract

Chlebowski RT et al. Ethnicity and breast cancer: Factors inf luencing differences in incidence and outcome. J Natl Cancer Inst 2005;97(6):439-48. Abstract

Chlebowski RT et al. Insulin, physical activity, and caloric intake in postmenopausal women: Breast cancer implications. J Clin Oncol 2004;22(22):4507-13. Abstract

Grann V et al. Regional and racial disparities in breast cancer-specif ic mortality. Soc Sci Med 2005;[Epub ahead of print]. Abstract

Hebert JR et al. Differences between estimated caloric requirements and self-reported caloric intake in the women’s health initiative. Ann Epidemiol 2003;13(9):629-37. Abstract

Howell A et al. Results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trail 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract

Joslyn SA et al. Racial and ethnic disparities in breast cancer rates by age: NAACCR Breast Cancer Project. Breast Cancer Res Treat 2005;92(2):97-105. Abstract

Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41(12):1678-89. Abstract

Rossouw JE et al. Risks and benef its of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33. Abstract

Thürlimann B et al. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Proc ASCO 2005;Abstract 511.

Tsubura A et al. Dietary factors modifying breast cancer risk and relation to time of intake. J Mammary Gland Biol Neoplasia 2005;10(1):87-100. Abstract

 

 
 
 
     
 
 

 
Editor’s Note:
Perspective from another world
 
Rowan T Chlebowski, MD, PhD
- Select publications
 
Eric P Winer, MD
- Select publications
 
Harry D Bear, MD, PhD
- Select publications
 
PowerPoint Presentations
Rowan T Chlebowski, MD, PhD
Kathy D Miller, MD
 
Editor's Office
Faculty Disclosures
CME Information